What does UFP Technologies do?
UFP Technologies, Inc. is a Nasdaq-listed contract development and manufacturing organization, or CDMO, focused on single-use and single-patient medical devices. It helps customers turn concepts into manufacturable components, sterile packages, subassemblies, or complete disposable devices. Its expertise spans foams, films, plastics, specialty fabrics, adhesives, molding, welding, thermoforming, precision converting, and clean-room assembly.
The company is more than a generic packaging converter: its products support robotic surgery, minimally invasive procedures, infection prevention, wound care, orthopedic implants, patient transfer systems, catheter packaging, wearables, diagnostics, and biopharma manufacturing. The official company site presents MedTech and Advanced Components, while SEC reporting treats the enterprise as one operating and reportable segment.
| Identity item | UFP Technologies profile | Why it matters |
|---|---|---|
| Listing | UFP Technologies, Inc. (Nasdaq: UFPT) | A specialized public manufacturer rather than the much larger UFP Industries. |
| Reporting structure | One operating and reportable segment | Investors must analyze markets, customers, acquisitions, and capabilities rather than rely on formal segment profit disclosure. |
| Core end market | Medical: 93.0% of Q1 2026 sales | The valuation story is increasingly tied to outsourced MedTech manufacturing. |
| Quality footprint | 19 ISO 13485-certified locations; 13 FDA-registered locations | Regulated manufacturing credentials raise qualification barriers for new suppliers. |
| Workforce | 4,846 full-time employees and 503 temporary workers as of January 24, 2026 | Labor availability, training, and productivity are economically material. |
How does UFP Technologies make money?
UFP earns most revenue from custom manufactured products. FY2025 product revenue was $591.4 million, versus $6.9 million from engineering services and $4.5 million from tooling and machinery. Engineering collaboration starts the relationship, but recurring commercial production supplies the larger economics once a program is validated and scaled.
Where does revenue come from?
How concentrated is the customer base?
Customer concentration is unusually important. In Q1 2026, the two largest customers represented 24.8% and 22.1% of sales; together they accounted for 46.9%. For FY2025, Intuitive Surgical SARL and Stryker represented 24.3% and 21.5%, respectively. This concentration can deepen relationships and create high-volume programs, but it also gives a small number of customers meaningful bargaining and forecasting power.
What does UFP Technologies' latest quarter show?
The latest official period is Q1 2026. The May 4, 2026 earnings release and the corresponding Form 10-Q show moderate top-line growth, stable operating profit, and a temporary cash-conversion problem driven by working capital. Medical sales grew 5.9%, while non-medical sales declined 15.0%. Management identified robotic surgery, patient surfaces and support, and interventional and surgical as the strongest medical sub-markets, growing 7%, 11%, and 15%, respectively.
| Metric | Q1 2026 | Q1 2025 | Interpretation |
|---|---|---|---|
| Net sales | $154.2M | $148.1M | Growth was 4.1%, but organic sales were essentially flat. |
| Gross profit | $44.4M | $42.2M | Robotic-surgery efficiencies helped gross margin reach 28.8%. |
| SG&A | $21.0M | $18.7M | Expense grew 12.3%, faster than revenue, including added staff, legal expense, and share compensation. |
| Operating income | $23.4M | $23.1M | Operating margin was approximately 15.2%, nearly flat year over year. |
| Net income | $17.5M | $17.2M | Lower interest expense partly offset operating-cost pressure. |
| Operating cash flow | $3.2M | $13.8M | Receivables rose $15.7M and inventories rose $7.2M, absorbing cash. |
| Capital expenditure | $1.7M | $2.8M | Quarterly free cash flow was about $1.5M before acquisitions and financing. |
Which strategic turning points created today's UFP Technologies?
UFPT's present model is the result of a deliberate shift toward regulated, higher-value medical manufacturing. The history that matters is not corporate trivia; it is the sequence of capability additions and geographic moves that expanded the addressable program set.
-
1993The current Delaware corporation was incorporated, establishing the public-company structure used today.
-
2018Dielectrics strengthened medical-device fabrication and expanded UFP's ability to deliver finished and semi-finished medical products.
-
2021-2022Contech Medical, DAS Medical, and Advant Medical added catheter and guidewire packaging, Dominican Republic production, Galway development resources, Costa Rica operations, and broader clean-room manufacturing.
-
2024Marble Medical, AJR Enterprises, Welch Fluorocarbon, and AQF Medical broadened adhesives, patient handling, implantable-device films, and Asian manufacturing exposure. The AJR transaction alone cost about $110.7M net of cash acquired.
-
2025AJR Specialty, AJR Custom Foam, TPI, and UNIPEC expanded capacity and film or thermoplastic-molding capabilities. Acquired businesses contributed $168.3M of FY2025 sales versus $73.1M in FY2024.
-
2026Mitchell Rock became CEO effective June 4, 2026, while the company prepared two additional Dominican Republic facilities and ramped four large programs.
What gives UFP Technologies a competitive advantage?
UFPT's moat is not primarily a consumer brand or a single patent. It is a bundle of difficult-to-replicate operational resources: engineering know-how, approved quality systems, specialty-material access, process breadth, clean-room manufacturing, international capacity, and customer-specific production history. The 2025 Form 10-K reports 21 active patents with expirations ranging from 2026 through 2044, but it also makes clear that preferred-supplier status, reliability, manufacturing location, price, service, materials access, and engineering expertise are central selection criteria.
Why can customer qualification create switching costs?
Medical customers often require suppliers to work within FDA-registered and ISO 13485-certified facilities. Once a component, material, process, and production site are validated as part of a regulated device, moving the work can require requalification, documentation, testing, and operational risk. These are not absolute barriers—customers can dual-source or transfer programs—but they make dependable execution more valuable than the apparent simplicity of an individual foam, film, or package.
| Moat resource | Evidence | Economic effect |
|---|---|---|
| Quality footprint | 19 ISO 13485-certified and 13 FDA-registered locations | Supports regulated production and raises the cost of supplier substitution. |
| Manufacturing breadth | Molding, thermoforming, laminating, precision cutting, welding, clean-room assembly, and specialty fabrics | Lets UFP solve multi-process programs and cross-sell capabilities. |
| Global footprint | 36.0% of long-lived assets outside the United States at March 31, 2026 | Enables lower-cost production and proximity to customer manufacturing hubs. |
| Intellectual property | 21 active patents as of the 2025 10-K | Adds targeted protection, though process knowledge and execution are more important than patents alone. |
Who competes with UFP Technologies, and where is it positioned?
UFP says competition comes primarily from smaller companies focused on particular industries or regions. The broader field includes medical-device contract manufacturers such as Integer Holdings, Viant, and Resonetics, plus diversified groups with healthcare operations. Direct overlap varies by program, material, process, and geography.
What decides a contract-manufacturing win?
| Competitive factor | UFPT position | Pressure point |
|---|---|---|
| Engineering collaboration | Strong in materials selection, prototyping, and design-for-manufacture | Customers can compare UFP with specialist engineering firms and larger CDMOs. |
| Qualification and quality | Broad certified footprint and existing preferred-supplier relationships | A serious quality failure could reverse the switching-cost advantage. |
| Cost and location | U.S., Ireland, Mexico, Central America, and Caribbean operations | Tariffs, wages, labor stability, and freight can alter the landed-cost comparison. |
| Program breadth | Foams, films, fabrics, adhesives, molding, packaging, and assembly | Larger rivals can offer capabilities beyond UFP's current portfolio. |
How financially strong is UFP Technologies?
FY2025 sales increased 19.5% to $602.8 million, but organic growth was 1.5% and acquired companies generated $168.3 million of sales. Gross margin declined to 28.3% from 29.1%, partly because the AJR labor issue added more than $6.3 million to cost of sales. Operating income increased 14.1% to $92.3 million and net income rose 15.8% to $68.3 million. The company's record 2025 results release provides the annual detail.
What does the multi-year revenue trend show?
How good is cash conversion?
Annual free cash flow was strong, but Q1 2026 showed working-capital volatility. The company produced $17.5 million of net income but only $3.2 million of operating cash flow because working-capital movements absorbed about $24.5 million. A DCF should normalize cash conversion across several quarters.
| Financial-health item | Latest value | Period | Implication |
|---|---|---|---|
| Cash | $20.0M | March 31, 2026 | A modest cash balance relative to acquisition-funded debt. |
| Total debt | $137.6M | March 31, 2026 | Includes a $106.3M term loan and $31.4M revolver balance. |
| Weighted average rate | 5.0% | March 31, 2026 | Interest expense fell as average debt declined, but floating-rate exposure remains. |
| Stockholders' equity | $438.9M | March 31, 2026 | Equity has grown through retained earnings; no dividend was paid in 2025. |
| Goodwill plus intangibles | $334.5M | March 31, 2026 | Acquisition accounting is a major balance-sheet feature and creates impairment sensitivity. |
| Credit facilities | $275.0M | Maturity June 27, 2029 | Capacity supports growth, but covenants and secured borrowing constrain capital allocation. |
Who owns UFP Technologies stock, and why does governance matter?
UFPT has one common share class and a dispersed institutional investor base rather than founder voting control. According to the 2026 proxy statement, BlackRock beneficially owned 14.19%, Wasatch Advisors 10.12%, Vanguard 6.90%, and Congress Asset Management 5.70%. Directors and executive officers as a group owned 4.59% as of April 10, 2026, while longtime CEO R. Jeffrey Bailly owned 2.20%.
What does the leadership transition change?
Mitchell Rock became chief executive officer effective June 4, 2026 after serving as company president and previously leading UFP MedTech. His long operating history reduces outsider-transition risk, but it also makes execution accountability clearer: the next phase depends on integrating acquired capabilities, restoring AJR productivity, ramping new Dominican Republic capacity, and converting large program launches into margin and cash flow.
| Holder or group | Shares | Ownership | Source period | Governance relevance |
|---|---|---|---|---|
| BlackRock | 1,097,570 | 14.19% | Proxy based on Feb. 12, 2026 filing | Largest disclosed institutional position. |
| Wasatch Advisors | 782,708 | 10.12% | January 30, 2026 | A concentrated active holder can influence expectations around growth and capital discipline. |
| Vanguard | 533,578 | 6.90% | December 31, 2025 | Represents passive institutional ownership and governance voting. |
| Congress Asset Management | 441,122 | 5.70% | December 31, 2025 | Another meaningful institutional block. |
| Directors and officers | 357,692 | 4.59% | April 10, 2026 | Provides economic alignment without management control. |
What opportunities could accelerate UFP Technologies' growth?
The strongest opportunities are attached to specific programs and capacity, not a vague claim that healthcare demand will grow. Management said four large programs were ramping in Q1 2026 and expected to become significant contributors in the second half. Two new Dominican Republic facilities—one in La Romana for robotic surgery and one in Santiago for patient-handling growth and program transfers—were expected to add capacity. The commercial agreements with Stryker are also important: a March 2025 Form 8-K disclosed exclusive manufacturing rights over a significant portion of acquired AJR business.
Which growth engines are most credible?
What risks could weaken the UFP Technologies story?
The central risk is concentration combined with execution. Intuitive Surgical and Stryker represented 45.8% of FY2025 revenue, while the two largest customers represented 46.9% in Q1 2026. A delayed program, inventory correction, price concession, insourcing decision, or supplier reallocation could materially change growth and utilization.
Which operating risks deserve the closest attention?
| Risk or valuation driver | Current anchor | Metric to monitor | DCF relevance |
|---|---|---|---|
| Organic growth | 1.5% in FY2025; essentially flat in Q1 2026 | Organic sales excluding acquisitions | Determines whether terminal growth is supported by the existing platform. |
| Gross margin | 28.3% FY2025; 28.8% Q1 2026 | Labor efficiency and product mix | Small changes materially affect operating profit and free cash flow. |
| Customer concentration | Top two: 46.9% of Q1 2026 sales | Share by customer and contract duration | Raises forecast and terminal-risk sensitivity. |
| Cash conversion | $3.2M operating cash flow in Q1 2026 | Receivable days, inventory, and capex | Revenue growth has less value if working capital consumes the cash. |
| Capital allocation | No FY2025 dividend; earnings retained for operations and acquisitions | Deal multiples, debt reduction, and post-deal organic growth | Acquisition returns determine whether reinvestment creates or dilutes value. |
What is the key takeaway from UFP Technologies analysis?
UFP Technologies has transformed a materials-conversion heritage into a specialized medical-device manufacturing platform. More than 90% of revenue now comes from medical markets, supported by a regulated footprint across robotic surgery, patient handling, interventional devices, sterile packaging, and implant components. Acquisitions helped lift revenue from $400.1 million in FY2023 to $602.8 million in FY2025.
Why does the business model matter for valuation?
Valuation should not extrapolate acquisition-driven growth without adjustment. Key assumptions are organic program growth, margin recovery, SG&A discipline, normalized working capital, capex, debt reduction, and acquisition returns. Q1 2026 medical growth and a 28.8% gross margin were constructive, but organic sales were essentially flat and operating cash flow was only $3.2 million.
What should students and investors monitor next?
- Growth and profitability of robotic surgery, patient surfaces and support, and interventional and surgical programs.
- AJR labor efficiency and whether the FY2025 cost burden fully recedes.
- Revenue from four large ramping programs and new Dominican Republic capacity.
- Organic growth versus acquired growth, especially after the 2024-2025 acquisition wave.
- Gross margin, operating margin, receivables, inventory, and free cash flow conversion.
- Debt, interest expense, and the price and strategic logic of any new acquisition.
- Customer concentration and contract durability with Intuitive Surgical and Stryker.
- Cyber, quality, regulatory, and international manufacturing execution.
Readers seeking the latest filings and governance materials can use the company's investor-relations page.
5-Year Financial Model
40+ Charts & Metrics
DCF & Multiple Valuation
Free Email Support
Disclaimer
All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.
We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site—including articles or product references—constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.
All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.